JP4615315B2 - 内皮依存性血管作用を決定するための方法 - Google Patents
内皮依存性血管作用を決定するための方法 Download PDFInfo
- Publication number
- JP4615315B2 JP4615315B2 JP2004558325A JP2004558325A JP4615315B2 JP 4615315 B2 JP4615315 B2 JP 4615315B2 JP 2004558325 A JP2004558325 A JP 2004558325A JP 2004558325 A JP2004558325 A JP 2004558325A JP 4615315 B2 JP4615315 B2 JP 4615315B2
- Authority
- JP
- Japan
- Prior art keywords
- pressure
- blood vessel
- related signal
- parameter
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 79
- 230000001419 dependent effect Effects 0.000 title claims abstract description 63
- 210000003038 endothelium Anatomy 0.000 title claims description 59
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 71
- 230000008859 change Effects 0.000 claims abstract description 33
- 210000002216 heart Anatomy 0.000 claims description 85
- 230000008753 endothelial function Effects 0.000 claims description 47
- 230000007246 mechanism Effects 0.000 claims description 39
- 210000003403 autonomic nervous system Anatomy 0.000 claims description 37
- 230000000638 stimulation Effects 0.000 claims description 37
- 210000001367 artery Anatomy 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 28
- 238000004458 analytical method Methods 0.000 claims description 26
- 230000009471 action Effects 0.000 claims description 20
- 210000002302 brachial artery Anatomy 0.000 claims description 17
- 230000010339 dilation Effects 0.000 claims description 16
- 238000012545 processing Methods 0.000 claims description 14
- 210000001715 carotid artery Anatomy 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 11
- 230000004936 stimulating effect Effects 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- 230000003340 mental effect Effects 0.000 claims description 7
- 210000002321 radial artery Anatomy 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 239000000919 ceramic Substances 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 abstract description 15
- 238000012360 testing method Methods 0.000 description 52
- 238000005259 measurement Methods 0.000 description 51
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 41
- 230000008694 endothelial dysfunction Effects 0.000 description 34
- 206010048554 Endothelial dysfunction Diseases 0.000 description 32
- 230000002792 vascular Effects 0.000 description 30
- 230000002159 abnormal effect Effects 0.000 description 29
- 230000001965 increasing effect Effects 0.000 description 18
- 238000002604 ultrasonography Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000011084 recovery Methods 0.000 description 16
- 230000009257 reactivity Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 230000008602 contraction Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000010586 diagram Methods 0.000 description 11
- 230000002889 sympathetic effect Effects 0.000 description 11
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 10
- 239000000006 Nitroglycerin Substances 0.000 description 10
- 208000029078 coronary artery disease Diseases 0.000 description 10
- 229960003711 glyceryl trinitrate Drugs 0.000 description 10
- 201000001320 Atherosclerosis Diseases 0.000 description 9
- 230000001734 parasympathetic effect Effects 0.000 description 9
- 206010047139 Vasoconstriction Diseases 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 8
- 210000004351 coronary vessel Anatomy 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000004872 arterial blood pressure Effects 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000036544 posture Effects 0.000 description 7
- 230000025033 vasoconstriction Effects 0.000 description 7
- 206010020565 Hyperaemia Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000000297 inotrophic effect Effects 0.000 description 5
- 238000010183 spectrum analysis Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000004865 vascular response Effects 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 238000005314 correlation function Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000008035 nerve activity Effects 0.000 description 4
- 208000022064 reactive hyperemia Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 3
- 210000001765 aortic valve Anatomy 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000001013 sinoatrial node Anatomy 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010053648 Vascular occlusion Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 108091008698 baroreceptors Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000012623 in vivo measurement Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000008288 physiological mechanism Effects 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 210000001774 pressoreceptor Anatomy 0.000 description 2
- 230000035485 pulse pressure Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 210000002820 sympathetic nervous system Anatomy 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000012285 ultrasound imaging Methods 0.000 description 2
- 230000001515 vagal effect Effects 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 230000003845 vascular endothelial function Effects 0.000 description 2
- 239000002550 vasoactive agent Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 230000000283 vasomotion Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 102000003727 Caveolin 1 Human genes 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 201000001962 aortic atherosclerosis Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000035581 baroreflex Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000037198 cardiovascular physiology Effects 0.000 description 1
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002517 constrictor effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000718 qrs complex Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 230000024977 response to activity Effects 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000955 splenic vein Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/02133—Measuring pressure in heart or blood vessels by using induced vibration of the blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
- A61B5/02405—Determining heart rate variability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/026—Measuring blood flow
- A61B5/0285—Measuring or recording phase velocity of blood waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4029—Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
- A61B5/4035—Evaluating the autonomic nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/416—Evaluating particular organs or parts of the immune or lymphatic systems the spleen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7253—Details of waveform analysis characterised by using transforms
- A61B5/726—Details of waveform analysis characterised by using transforms using Wavelet transforms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43173902P | 2002-12-09 | 2002-12-09 | |
| PCT/IL2003/001025 WO2004052196A1 (en) | 2002-12-09 | 2003-12-03 | Method for determining endothelial dependent vasoactivity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006516000A JP2006516000A (ja) | 2006-06-15 |
| JP2006516000A5 JP2006516000A5 (enExample) | 2007-01-25 |
| JP4615315B2 true JP4615315B2 (ja) | 2011-01-19 |
Family
ID=32507789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004558325A Expired - Fee Related JP4615315B2 (ja) | 2002-12-09 | 2003-12-03 | 内皮依存性血管作用を決定するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7374541B2 (enExample) |
| EP (1) | EP1569550B1 (enExample) |
| JP (1) | JP4615315B2 (enExample) |
| AT (1) | ATE471692T1 (enExample) |
| AU (1) | AU2003302882B2 (enExample) |
| CA (1) | CA2508590A1 (enExample) |
| DE (1) | DE60333120D1 (enExample) |
| WO (1) | WO2004052196A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003302882B2 (en) | 2002-12-09 | 2008-06-19 | Ramot At Tel Aviv University Ltd. | System for determining endothelial dependent vasoactivity |
| US7771364B2 (en) | 2004-01-27 | 2010-08-10 | Spirocor Ltd. | Method and system for cardiovascular system diagnosis |
| US7131949B2 (en) * | 2004-04-13 | 2006-11-07 | Omron Healthcare Co., Ltd. | Method and apparatus for examining vascular endothelial functions |
| US7664551B2 (en) * | 2004-07-07 | 2010-02-16 | Medtronic Transneuronix, Inc. | Treatment of the autonomic nervous system |
| EP1785088A1 (en) * | 2005-11-14 | 2007-05-16 | Congener Wellness Corp. | A system and method for the management and control of cardiovascular related diseases, such as hypertension |
| RU2309668C1 (ru) | 2006-02-20 | 2007-11-10 | Александр Сергеевич Парфенов | Способ неинвазивного определения функции эндотелия и устройство для его осуществления |
| JP4802324B2 (ja) * | 2006-02-22 | 2011-10-26 | 国立大学法人 名古屋工業大学 | 脈診解析のための脈波測定装置 |
| US7894900B2 (en) * | 2006-08-30 | 2011-02-22 | Smartimplant OÜ | Device and method for monitoring cardiac pacing rate |
| JP5441707B2 (ja) | 2006-12-09 | 2014-03-12 | マシモ コーポレイション | プレチスモグラフ変動プロセッサ |
| US8100834B2 (en) * | 2007-02-27 | 2012-01-24 | J&M Shuler, Inc. | Method and system for monitoring oxygenation levels of a compartment for detecting conditions of a compartment syndrome |
| CN102579082B (zh) * | 2007-06-04 | 2014-05-28 | 柯尼卡美能达株式会社 | 超声波诊断装置及用于超声波诊断装置的超声波探头 |
| JP2009178456A (ja) * | 2008-01-31 | 2009-08-13 | Nippon Koden Corp | 自律神経活動計測装置及び計測方法 |
| JP5192859B2 (ja) * | 2008-03-17 | 2013-05-08 | 株式会社ユネクス | 生体血管状態測定装置 |
| WO2010056538A1 (en) * | 2008-10-29 | 2010-05-20 | Tim Maguire | An automated vessel puncture device using three-dimensional(3d) near infrared (nir) imaging and a robotically driven needle |
| JP5167156B2 (ja) * | 2009-01-19 | 2013-03-21 | 株式会社デンソー | 生体状態評価装置、生体状態評価システム、プログラム、及び記録媒体 |
| US8057400B2 (en) * | 2009-05-12 | 2011-11-15 | Angiologix, Inc. | System and method of measuring changes in arterial volume of a limb segment |
| ITPI20090099A1 (it) * | 2009-07-31 | 2011-02-01 | Cnr Consiglio Naz Delle Ric Erche | Apparecchiatura per la misura della velocità di propagazione di un'onda pressoria nel sistema arterioso |
| US8668649B2 (en) * | 2010-02-04 | 2014-03-11 | Siemens Medical Solutions Usa, Inc. | System for cardiac status determination |
| GB2478291A (en) * | 2010-03-02 | 2011-09-07 | Univ Lancaster | Endothelium assessment probe |
| US9307928B1 (en) | 2010-03-30 | 2016-04-12 | Masimo Corporation | Plethysmographic respiration processor |
| JP5518554B2 (ja) * | 2010-04-16 | 2014-06-11 | 酒井医療株式会社 | 血管硬さ評価システム及び血管硬さ指標の算出方法 |
| WO2012021765A2 (en) * | 2010-08-12 | 2012-02-16 | Board Of Trustees Of Michigan State University | Methods and apparatus for determining arterial pulse wave velocity |
| US9320445B2 (en) | 2011-05-17 | 2016-04-26 | Siemens Medical Solutions Usa, Inc. | System for cardiac condition detection responsive to blood pressure analysis |
| US10398323B2 (en) * | 2012-08-28 | 2019-09-03 | Board Of Trustees Of Michigan State University | Methods and apparatus for determining pulse transit time as a function of blood pressure |
| JP5571234B2 (ja) * | 2013-06-26 | 2014-08-13 | 日本光電工業株式会社 | 自律神経活動計測装置 |
| JP6349075B2 (ja) * | 2013-11-22 | 2018-06-27 | 三星電子株式会社Ｓａｍｓｕｎｇ Ｅｌｅｃｔｒｏｎｉｃｓ Ｃｏ．，Ｌｔｄ． | 心拍数測定装置及び心拍数測定方法 |
| US10945612B2 (en) | 2014-04-03 | 2021-03-16 | The Regents Of The University Of California | Assessing endothelial function using a blood pressure cuff |
| US10105089B2 (en) | 2014-06-18 | 2018-10-23 | Hong Kong Applied Science And Technology Research Institute Co., Ltd. | Systems and methods for blood pressure measurement with psychological status validation |
| US10588577B2 (en) | 2015-01-29 | 2020-03-17 | Siemens Healthcare Gmbh | Patient signal analysis based on affine template matching |
| CN108135506B (zh) * | 2015-08-14 | 2021-11-02 | 加利福尼亚大学董事会 | 用于评估哺乳动物中的内皮功能的方法和装置 |
| CN110248596B (zh) | 2016-12-15 | 2022-12-20 | 巴克斯特国际公司 | 用于从感测的静脉波形监视和确定患者参数的系统和方法 |
| US20180192916A1 (en) * | 2017-01-10 | 2018-07-12 | General Electric Company | Imaging system for diagnosing patient condition |
| US11039754B2 (en) | 2018-05-14 | 2021-06-22 | Baxter International Inc. | System and method for monitoring and determining patient parameters from sensed venous waveform |
| EP3782542B1 (en) * | 2019-08-20 | 2024-04-10 | Stichting IMEC Nederland | A method and system for microcirculation function assessment |
| JP7560822B2 (ja) * | 2020-02-25 | 2024-10-03 | 日本光電工業株式会社 | 生体情報処理装置、生体情報処理方法、プログラム及び記憶媒体 |
| RU2751817C1 (ru) * | 2020-08-31 | 2021-07-19 | Закрытое Акционерное Общество "Ес-Лизинг" | Компьютеризированный способ неинвазивного выявления нарушений углеводного обмена по вариабельности сердечного ритма и носимое автономное устройство для его реализации |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3623476A (en) * | 1970-02-16 | 1971-11-30 | Philips Corp | Blood pressure measurement apparatus |
| US5111826A (en) * | 1984-12-07 | 1992-05-12 | Nasiff Roger E | Indirect continuous blood pressure method |
| JP2979933B2 (ja) * | 1993-08-03 | 1999-11-22 | セイコーエプソン株式会社 | 脈波解析装置 |
| JPH08266489A (ja) * | 1995-03-29 | 1996-10-15 | Nippon Ham Kk | 動脈硬化部位の検出方法 |
| JPH11128185A (ja) * | 1997-10-31 | 1999-05-18 | Matsushita Electric Ind Co Ltd | 心拍変動解析方法および装置 |
| IL124787A0 (en) * | 1998-06-07 | 1999-01-26 | Itamar Medical C M 1997 Ltd | Pressure applicator devices particularly useful for non-invasive detection of medical conditions |
| IL128482A (en) | 1999-02-11 | 2003-06-24 | Ultrasis Internat 1993 Ltd | Method and device for continuous analysis of cardiovascular activity of a subject |
| JP3027750B1 (ja) * | 1999-05-17 | 2000-04-04 | 日本コーリン株式会社 | 下肢上肢血圧指数測定装置および下肢血圧測定装置 |
| US6616613B1 (en) * | 2000-04-27 | 2003-09-09 | Vitalsines International, Inc. | Physiological signal monitoring system |
| NZ524765A (en) * | 2000-07-19 | 2006-10-27 | Nigel E Sharrock | Non-invasive measurement of suprasystolic signals |
| CA2424389C (en) * | 2000-10-23 | 2011-07-12 | Itamar Medical Ltd. | Method and apparatus for non-invasively evaluating endothelial activity in a patient |
| JP3590583B2 (ja) * | 2000-12-28 | 2004-11-17 | フクダ電子株式会社 | 血管内皮機能測定装置 |
| US20020149152A1 (en) | 2001-02-23 | 2002-10-17 | Alan Taylor | Multiple-stage game of chance and method of and system for playing the game |
| JP2002253519A (ja) * | 2001-03-01 | 2002-09-10 | Nippon Koden Corp | 血液量測定方法及び生体信号モニタ装置 |
| JP2002291709A (ja) * | 2001-03-30 | 2002-10-08 | Nippon Colin Co Ltd | 圧脈波検出装置 |
| JP3533406B2 (ja) * | 2001-07-02 | 2004-05-31 | コーリンメディカルテクノロジー株式会社 | 動脈硬化評価装置 |
| GB0205653D0 (en) * | 2002-03-11 | 2002-04-24 | Micro Medical Ltd | A method of measuring endothelial function in a person |
| AU2003302882B2 (en) | 2002-12-09 | 2008-06-19 | Ramot At Tel Aviv University Ltd. | System for determining endothelial dependent vasoactivity |
| US20060195035A1 (en) * | 2005-02-28 | 2006-08-31 | Dehchuan Sun | Non-invasive radial artery blood pressure waveform measuring apparatus system and uses thereof |
| JP4752673B2 (ja) * | 2005-10-06 | 2011-08-17 | コニカミノルタセンシング株式会社 | 脈波データ解析方法、システム、プログラム |
-
2003
- 2003-12-03 AU AU2003302882A patent/AU2003302882B2/en not_active Expired - Fee Related
- 2003-12-03 DE DE60333120T patent/DE60333120D1/de not_active Expired - Lifetime
- 2003-12-03 AT AT03812666T patent/ATE471692T1/de not_active IP Right Cessation
- 2003-12-03 WO PCT/IL2003/001025 patent/WO2004052196A1/en not_active Ceased
- 2003-12-03 CA CA002508590A patent/CA2508590A1/en not_active Abandoned
- 2003-12-03 JP JP2004558325A patent/JP4615315B2/ja not_active Expired - Fee Related
- 2003-12-03 US US10/537,913 patent/US7374541B2/en not_active Expired - Fee Related
- 2003-12-03 EP EP03812666A patent/EP1569550B1/en not_active Expired - Lifetime
-
2008
- 2008-04-25 US US12/149,100 patent/US8187196B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8187196B2 (en) | 2012-05-29 |
| DE60333120D1 (de) | 2010-08-05 |
| EP1569550B1 (en) | 2010-06-23 |
| US7374541B2 (en) | 2008-05-20 |
| JP2006516000A (ja) | 2006-06-15 |
| AU2003302882A1 (en) | 2004-06-30 |
| CA2508590A1 (en) | 2004-06-24 |
| US20060149152A1 (en) | 2006-07-06 |
| AU2003302882B2 (en) | 2008-06-19 |
| US20080200820A1 (en) | 2008-08-21 |
| ATE471692T1 (de) | 2010-07-15 |
| EP1569550A1 (en) | 2005-09-07 |
| WO2004052196A1 (en) | 2004-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4615315B2 (ja) | 内皮依存性血管作用を決定するための方法 | |
| US20070021673A1 (en) | Method and system for cardiovascular system diagnosis | |
| US7771364B2 (en) | Method and system for cardiovascular system diagnosis | |
| JP5918803B2 (ja) | 内皮機能の非侵襲的評価のための方法および装置 | |
| US6616613B1 (en) | Physiological signal monitoring system | |
| US20080045844A1 (en) | Method and system for cardiovascular system diagnosis | |
| US20100152592A1 (en) | Assessment of Preload Dependence and Fluid Responsiveness | |
| US20200229774A1 (en) | Method to Quantify Hypertension, Aging Status and Vascular Properties in Vivo from Arterial Optical Plethysmograph Waveform Measurements | |
| AU2006231931A1 (en) | System and method for non-invasive cardiovascular assessment from supra-systolic signals obtained with a wideband external pulse transducer in a blood pressure cuff | |
| JP2006528023A (ja) | 心拍数変動に基づいて心虚血を評価するための方法およびシステム | |
| EP3911228B1 (en) | A method to quantify the hemodynamic and vascular properties in vivo from arterial waveform measurements | |
| CN104970784A (zh) | 辅助检测心血管疾病中脉波压力振幅数值的获取方法及装置 | |
| Mulligan et al. | Evaluation of a Novel Non-invasive Algorithm to Assess Systolic and Diastolic Function in Normal Subjects | |
| Fabián | Brachial occlusion method for non-invasive diagnostics of cardiovascular system | |
| RU2712045C1 (ru) | Способ пьезопульсометрической оценки характера автономной регуляции сердечно-сосудистой системы у человека | |
| Siegelová et al. | Blood Pressure Measurement in 30 Years of Noninvasive Methods of Cardiology in Masaryk University Brno, Czech Republic: Measurement of Blood Pressure with Cuff and Cuffless Blood Pressure Measurement in 2022 According to European Society of Hypertension | |
| Dehghanojamahalleh | Development of a Novel System for the Analysis of the Cardiovascular and Autonomic Nervous Systems | |
| Badi et al. | Patterns of digital volume pulse waveform and pulse transit time in young and older individuals | |
| Edwards | Modeling of arterial hemodynamics | |
| Shin | PERSONALIZED TRAITS MONITORING USING A NEURAL NETWORK BASED ON OSCILLOMETRIC MEASUREMENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090717 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091014 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100507 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101001 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101020 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131029 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |